ClinicalTrials.Veeva

Menu

Feasibility - Infinitome

HealthPartners Institute logo

HealthPartners Institute

Status

Completed

Conditions

Alzheimer Disease

Treatments

Procedure: Infinitome

Study type

Observational

Funder types

Other

Identifiers

NCT04563767
A20-199

Details and patient eligibility

About

The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI). This technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning cognitively eloquent brain regions during surgical operations. The potential of Infinitome in identifying connectome dysfunction for neurodegenerative diseases such as Alzheimer's disease has yet to be explored. This diagnostic technique may play a critical role for identifying disease brain networks that may benefit from targeted interventions in clinical trials.

Enrollment

4 patients

Sex

All

Ages

40 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with a diagnosis of mild, moderate, or severe Alzheimer's disease
  2. Age: 40 - 90 Years
  3. Patients who are clinically indicated for an MRI

Exclusion criteria

  1. fMRI contraindicated (eg. Implantable device, pacemaker, metallic implants, etc.)
  2. Subject unable to tolerate sitting for a one hour fMRI
  3. Other concerns as determined by the investigator

Trial design

4 participants in 1 patient group

Infinitome
Description:
All patients will be in the same cohort. No intervention will be administered. Patients will undergo a structural magnetic resonance imaging (MRI) as part of their standard of care. Added on will be the resting state fMRI (rs-fMRI). The rs-fMRI data will be analyzed.
Treatment:
Procedure: Infinitome

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems